Larin Fe

Quick links to important sections

Larin Fe

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Larin Fe

Property Description
Active Ingredients Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate
Form Oral Tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Hormonal Compound

Larin Fe is a prescription-only, synthetic hormonal medication whose primary purpose is the effective prevention of pregnancy in women of reproductive age. It is classified as a low-dose product within the Combined Hormonal Contraceptive (CHC) pharmacological class, a category utilized for managing the female reproductive cycle.


Definition and Pharmacological Classification

This medication is defined by its combination of two synthetic sex hormones: the progestin Norethindrone Acetate and the estrogen Ethinyl Estradiol. As a combination oral contraceptive, it intervenes directly in the natural menstrual cycle to achieve its high-level therapeutic purpose. This specific hormonal combination demonstrates consistent efficacy in preventing conception. Other products containing this same hormonal combination include Loestrin, Minastrin, and Junel, though the specific packaging format may vary.

Composition and Form: The 28-Day Oral Tablet

Larin Fe is supplied as an Oral Tablet in a 28-day continuous administration regimen package. The differentiating feature of this presentation is the inclusion of the non-hormonal, reminder pills that contain Ferrous Fumarate, an iron supplement. This specialized packaging facilitates the continuous daily pill-taking routine while also addressing the patient’s nutritional needs. The inclusion of the iron supplement in the reminder pills is a method to help mitigate the risk of iron-deficiency anemia that may result from menstrual blood loss.

Primary Therapeutic Purpose

Larin Fe's singular therapeutic focus is to act as birth control. It accomplishes the prevention of pregnancy through the systemic action of its combined hormonal components. This action involves suppressing the release of pituitary hormones, which in turn inhibits the primary reproductive event of ovulation. This method is typically used by women seeking a non-barrier, patient-controlled form of reliable contraception.

Regulatory References

  1. Norethindrone/Ethinyl Estradiol/Ferrous Fumarate

What side effects are possible with Larin Fe?

Serious Warnings and Safety Information

The use of combined oral contraceptives (COCs) is associated with an increased risk of several serious conditions, including thromboembolism, stroke, and myocardial infarction. The highest risk of these serious cardiovascular events is observed in women who smoke and are over 35 years of age, a patient group for whom this medication is contraindicated by regulatory guidance.

Serious and Clinically Significant Adverse Reactions

Adverse reactions documented in official sources include a risk of thrombotic events (e.g., deep vein thrombosis, pulmonary embolism, arterial thromboembolism), hepatic neoplasia (benign liver tumors/adenomas), gallbladder disease, and hypertension. The risk of stroke or blood clot is highest during the first year of use.

Common Adverse Reactions

The most frequently reported adverse reactions (ge 2% incidence) in clinical trials include headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, mood changes, bacterial vaginitis, acne, and weight gain. Irregular uterine bleeding or spotting, particularly in the initial cycles of use, is also a common occurrence.

Safety Restrictions and Monitoring

This medication is contraindicated in patients with a history of or current thrombotic disorders, severe or uncontrolled hypertension, known hormone-sensitive cancers (like breast cancer), liver disease or tumors, or those taking certain Hepatitis C combination drug regimens. Use should be discontinued at least four weeks before and for two weeks following major surgery or during periods of prolonged immobilization. For patients with prediabetes, diabetes, or controlled hypertension, regulatory guidelines mandate specific safety monitoring during use.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The official regulatory profile for Larin Fe overdose addresses risks related to both the hormonal and non-hormonal components.

Overdose Scope

Property Official Regulatory Statement
Documented Manifestations For the hormonal components: Nausea, vomiting, breast tenderness, headache, and drowsiness are documented presentations. Heavy withdrawal bleeding may also occur several days after the overdose. For the iron component: Initial symptoms may include stomach pain, vomiting, and diarrhea; severe presentations can involve seizure or unconsciousness [NIH MedlinePlus, NHS].
Life-Threatening Risk The iron component (Ferrous Fumarate) carries a mandatory warning: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children younger than 6 years [FDA/DailyMed].
Immediate Action Required Patients must get medical help right away or call a poison control center immediately for any suspected overdose of iron-containing products [FDA/DailyMed, NIH MedlinePlus].

Connection to the Overall Overdose Profile:

Regulatory documents define the Larin Fe overdose profile around a critical severity difference: the hormonal components are generally not likely to be life-threatening, while the iron component dictates a non-negotiable emergency protocol due to its fatal poisoning risk to children. This explicit risk warning mandates that immediate medical help must be sought to address severe documented outcomes like systemic collapse or neurological events.

Therapeutic Uses of Larin Fe

This medication is primarily used as a combined oral contraceptive. Beyond its main role, it is relevant in contexts where additional symptomatic support is needed for common gynecological and dermatological conditions.

Regulation of Fertility and Symptomatic Support

This medication's primary use is to support effective, patient-controlled contraception in women of reproductive age. It is commonly used to help with the symptomatic relief of irregular menstrual cycles, severe cramping (Dysmenorrhea), and excessive blood loss (Menorrhagia), which are conditions characterized by periods of heightened symptoms. Furthermore, it is applied in addressing hormone-driven manifestations, such as moderate acne vulgaris.

“The combination of active ingredients supports patients by helping to regulate cycles and ease the overall burden of distressing symptoms.”

This regulation contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases. By managing heavy blood loss, which is a symptom that creates noticeable physiological strain, it provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Severe Menstrual Symptoms

Larin Fe is considered relevant for easing symptoms related to physical discomfort and systemic imbalance, particularly when menstrual cramps and heavy bleeding create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview of Ethinyl Estradiol and Norethindrone

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility for Larin Fe, a Combined Hormonal Contraceptive (CHC), is restricted by regulatory authorities to females of reproductive potential who do not have documented contraindications.

Classification Restricted Populations
Absolute Contraindication Females over age 35 who smoke; current or history of thrombotic diseases (e.g., DVT, pulmonary embolism, coronary artery disease); uncontrolled hypertension; migraines with aura; breast cancer; liver tumors or severe liver disease; or undiagnosed abnormal uterine bleeding.
Not Recommended Women who are pregnant (contraindicated); nursing mothers (due to potential for reduced milk production); and women in the immediate postpartum period (start no earlier than four weeks after delivery) [Source: FDA].
Age-Related Rule Not indicated for use in pre-menarcheal females; use is not established in older adults (geriatric population).
Special Consideration Efficacy has not been evaluated in women with a Body Mass Index (BMI) over 35 kg/m^2. Discontinuation is specified at least four weeks before and two weeks after major surgery due to thromboembolism risk.

These official statements define non-eligibility and conditional use based on underlying vascular risks and hormone-sensitive conditions, ensuring the medicine is only used by the patient population for which the risk profile is considered acceptable.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The use of this medication is subject to strict constraints defined by potential pharmacokinetic interactions and contraindicated combinations as described in regulatory documents.


Contraindicated Combinations

Co-administration with the combination drug regimen of Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, is formally prohibited due to the potential for significant elevations of liver enzymes (ALT). Additionally, the medication is contraindicated in females who are over 35 years of age and smoke, due to a serious risk of cardiovascular events.


Pharmacokinetic and Exposure Interactions

The primary drug-drug interactions involve effects on metabolic enzymes. Certain enzyme-inducing medicines, such as Rifampin and some Anticonvulsants (e.g., Phenytoin), are documented to accelerate the metabolism of the hormonal components, which may reduce contraceptive effectiveness. Conversely, inhibitors like Ascorbic Acid may increase the plasma concentration of Ethinyl Estradiol through the inhibition of conjugation. Co-administration can also increase the plasma levels of other medicines, including Cyclosporine and Theophylline. Herbal products, such as St. John’s Wort, may also decrease efficacy through enzyme induction.


Timing and Population Notes

The medication requires specific timing separation. The Ferrous Fumarate (iron) component's absorption is reduced by co-ingestion of dairy products, coffee, or tea, necessitating dose spacing. For patients completing the contraindicated Hepatitis C regimen, a mandated restart time of approximately two weeks is required. The regulatory label notes that hormonal components may be poorly metabolized in patients with hepatic impairment.

Mechanism of Action

Larin Fe, which contains the synthetic hormones norethindrone (a progestin) and ethinyl estradiol (an estrogen), mediates its primary mechanism of action by modulating the hypothalamic-pituitary-ovarian axis. The estrogen and progestin components act as agonists on their respective hormone receptors located primarily within the hypothalamus and pituitary gland. This interaction initiates a robust negative feedback signal that suppresses the release of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus.

The resulting reduction in GnRH activity leads to the downstream inhibition of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) secretion by the pituitary. This suppression of gonadotropins prevents the mid-cycle LH surge, thereby blocking the final stages of ovarian follicular development and the subsequent release of an ovum. Concurrently, the progestin component induces system-level physiological changes, including thickening the cervical mucus to impede sperm passage and modifying the cellular structure of the endometrium to reduce its receptivity. The ferrous fumarate is an inert component included to support a daily regimen and does not influence the hormonal cascade.

Dosage and Administration Information

Administration Guidelines

Larin Fe is administered exclusively via the oral route as a tablet. The regimen is structured as a continuous 28-day cycle, requiring one tablet to be taken daily at the same time each day.

The complete cycle consists of 21 or 24 active hormonal tablets followed by 7 or 4 non-hormonal tablets, which contain Ferrous Fumarate. The tablets must be taken in the sequential order designated on the blister pack, and a new pack must be started immediately following the completion of the prior one, ensuring no interval without a tablet.

This medication may be administered without regard to meals; however, taking it with food or at bedtime may assist with adherence. The use of Larin Fe begins with one of two methods: the Day 1 Start or the Sunday Start. For patients initiating treatment using the Sunday Start procedure, a non-hormonal barrier method must be used for the first seven days.

Specific administration rules apply to missed doses, which are complex and contingent upon the number of tablets missed and their position in the cycle; these situations require consulting the detailed patient information. Regarding population context, the efficacy of Larin Fe has not been clinically assessed in women with a Body Mass Index (BMI) greater than 35 kg/m^2.

Recent Clinical Evidence

Larin Fe: Recent Clinical Evidence

Evidence for use in Type 2 Diabetes Mellitus

Research exploring the drug's profile in Type 2 Diabetes Mellitus primarily involved Randomized Controlled Trials (RCTs) and observational studies. These studies monitored outcomes related to systemic or functional imbalance over defined time intervals. Researchers studied adult populations, including groups with existing cardiovascular conditions, to evaluate outcomes like glycated hemoglobin (HbA1c) and fasting plasma glucose. Findings described patterns where measurements of HbA1c values were measured across treatment and comparison groups. Uncertainty remains because the evidence quality varies across studies, and data for certain groups, such as children or very frail older adults, remains insufficient.

Evidence for use in Weight Management (Obesity)

The investigational drug was evaluated in multicenter, intermediate-duration Randomized Controlled Trials (RCTs). Research examined outcomes reflecting daily functioning, primarily focusing on body weight change and the number of people who reached pre-set weight loss goals. Studies also monitored measurements like waist circumference. The findings describe group patterns where measured weight loss was observed in the studied populations. What is still uncertain is the durability of these patterns over very long periods, as follow-up durations were limited in some key studies, and high rates of people leaving some longer trials affects the available data.

Long-term Studies and Follow-up

Research has explored outcomes over periods that extend to several years, primarily through long-term cardiovascular outcomes trials. These extended studies provide context but not individual predictions about long-term patterns, monitoring metrics related to major heart events. Long-term effects for the maintenance of observed weight patterns beyond the intermediate duration are not fully established. Overall, studies help show what has been observed so far, indicating data show patterns related to durability over time, but research is ongoing.

What is still uncertain about the Investigational Drug

The certainty remains low in several key areas. Follow-up durations were limited in some trials, particularly those focused on histological endpoints for Non-Alcoholic Steatohepatitis (NASH). Furthermore, evidence quality varies across studies, and research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes. Data for certain special groups remain insufficient, indicating that more research is needed to fully understand all aspects of the drug's profile.

Frequently Asked Questions (FAQ)

Common questions about Larin Fe (FAQ)


Q: Is Larin Fe the same as other birth control pills?

A: Larin Fe is classified as a Combined Hormonal Contraceptive (CHC). While it uses a common hormone combination, the specific dosages, the number of active pills, or the inclusion of the non-hormonal iron component may differ from other birth control pills. Official documents list other products that contain the same active hormonal components.


Q: How quickly does Larin Fe start to work?

A: Official administration guidelines indicate that protection may begin on the first day if Larin Fe is started on Day 1 of the menstrual period. If the medication is started at any other time, regulatory documents specify that a non-hormonal barrier method is needed for the first seven days. The requirement to use a barrier method helps establish contraceptive efficacy during the initial phase of use.


Q: Are there any specific supplements or vitamins that interact with Larin Fe?

A: Regulatory information notes that certain supplements may interact with Larin Fe. For instance, Ascorbic Acid (Vitamin C) may increase the plasma concentration of one of the hormonal ingredients. Herbal products like St. John’s Wort are also documented to reduce the medication's effectiveness. Regulatory documents mention that informing a healthcare provider about all supplements and vitamins is recommended.


Q: What are the signs of a serious side effect from Larin Fe that I should know about?

A: Serious symptoms that require immediate attention are listed in the official patient information. These include signs related to blood clots, such as sudden, severe headaches, slurred speech, sudden vision loss, stabbing chest pain, or unexplained pain/warmth in one leg.


Q: Is Larin Fe appropriate for women in their 40s?

A: Official prescribing information indicates that Larin Fe is formally contraindicated for females over 35 years of age who also smoke. This is due to a documented serious risk of cardiovascular events. For women in their 40s who do not smoke, eligibility is determined by the absence of other contraindications listed in the regulatory documents.


Q: Can Larin Fe be used for conditions other than contraception?

A: The primary therapeutic purpose of Larin Fe is the prevention of pregnancy. Official documents describe that combined oral contraceptives may offer non-contraceptive benefits. These benefits can include decreased menstrual blood loss, reduced painful periods, and acne treatment.


Q: What makes Larin Fe different from other pills that contain iron?

A: Larin Fe contains the specific synthetic hormones norethindrone acetate and ethinyl estradiol. The ferrous fumarate tablets are non-hormonal and are included to support the 28-day continuous daily regimen. The iron component may also help mitigate the risk of iron-deficiency anemia that may result from menstrual blood loss.


Q: How does Larin Fe affect the timing of my menstrual cycle?

A: According to the official product information, the anticipated withdrawal bleeding (similar to menstruation) typically begins two or three days after a user starts taking the brown, non-hormonal tablets. Bleeding may occasionally begin as late as the fourth or fifth day of taking the non-hormonal pills.


Q: What is the typical time frame for side effects to go away?

A: Official labeling describes that common adverse effects are usually most noticeable during the initial oral contraceptive cycle. For most individuals, these effects tend to diminish or disappear altogether after three or four monthly cycles of continuous use.


Q: Is Larin Fe considered effective based on clinical studies?

A: Studies and official information indicate that Larin Fe demonstrates high efficacy in preventing pregnancy. Clinical trials have reported a Pearl Index (a common measure of effectiveness) of less than 1 when the medication is used perfectly according to directions.


Q: What is the relationship between Larin Fe and depression?

A: Regulatory documents state that combined hormonal contraceptives have been associated with mood changes. This includes the possibility of new or worsening depression, which is listed as an adverse reaction that should be reported to a healthcare provider.


Q: Does Larin Fe help with periods that are very heavy?

A: Official documents suggest that combined oral contraceptives may lead to decreases in both menstrual blood loss and the frequency of painful periods. The ferrous fumarate component is included as a non-hormonal supplement to help mitigate the risk of iron-deficiency anemia potentially resulting from menstrual blood loss.


Q: What happens if I miss the iron pills (Fe) in the pack?

A: Regulatory instructions for missed pills specify that if any of the brown (non-hormonal) tablets in Week 4 are missed, they should be discarded. Since these pills are inert (non-hormonal), a back-up birth control method is not required, and the new pill pack should be started on its scheduled day.


Q: Does Larin Fe affect fertility after I stop taking it?

A: Official documents note that a possible adverse reaction following discontinuation is temporary infertility. However, regulatory sources state there is no evidence of an increased risk of birth defects in newborn babies when pregnancy occurs shortly after stopping the medication.


Q: Can Larin Fe interfere with antibiotics?

A: Regulatory documents state that certain broad-spectrum antibiotics and agents that cause severe gastrointestinal upset may reduce the effectiveness of the hormonal components. In addition, certain antibiotics may interfere with the absorption of the iron component.


Q: Does Larin Fe cause changes in my vision?

A: Problems with vision are noted in official prescribing information. Sudden vision loss is listed among the serious symptoms that regulatory documents state should be addressed immediately due to potential underlying health concerns.


Q: Is there a generic version of Larin Fe available?

A: Larin Fe is a generic drug that contains the active ingredients norethindrone acetate, ethinyl estradiol, and ferrous fumarate. There are other equivalent generic products available that share this same combination of hormonal components.


Q: Does taking Larin Fe affect routine lab test results?

A: According to official product labeling, the hormonal components of Larin Fe may interfere with the results of certain routine laboratory tests. These can include tests used to measure blood clotting factors and thyroid function.


Q: Is it true that Larin Fe can cause hair loss or thinning?

A: Changes in hair growth, including hair loss or thinning, have been associated with hormonal contraceptives. Although this is not listed as a common side effect (incidence ge 2% )), patients with concerns about changes in hair growth may wish to consult the official patient information.


Q: What should I do if my period stops completely while on Larin Fe?

A: Official documentation states that after several months of use, bleeding may become reduced to the point of virtual absence. However, if two consecutive expected periods are missed while the prescribed regimen has been followed, official guidance indicates that pregnancy must be ruled out before continuing the medication.


Q: If I get sick with vomiting or diarrhea, does Larin Fe still work?

A: Severe gastrointestinal upset, such as persistent vomiting or diarrhea, can impact the absorption of the hormonal components. Official patient information indicates this may reduce the medication's effectiveness. Patients can refer to the detailed patient information for specific guidance on how to proceed in this situation.


Q: Can Larin Fe change the way my contact lenses fit?

A: Official warnings state that hormonal contraceptives have been associated with changes in contact lens tolerance. If patients notice visual changes or lens discomfort, they may need to consult an eye care specialist, as described in official warnings.


Q: Does Larin Fe change my cholesterol levels?

A: Official warnings state that changes in lipid profiles, including high cholesterol and triglycerides, are a noted factor requiring consideration. Official warnings note that monitoring of these factors may be a consideration prior to and during the use of combined hormonal contraceptives.


Q: Is Larin Fe okay to use if I have thyroid issues?

A: The iron component may decrease the absorption of certain thyroid medications if taken at the same time. Furthermore, the hormonal components of Larin Fe are documented to interfere with thyroid-related laboratory test results.


Q: What are the typical expected results when using Larin Fe for period symptoms?

A: Studies and official product information indicate that expected non-contraceptive benefits can include a decrease in the amount of menstrual blood loss and a reduction in the frequency of painful periods.


Q: How long does Larin Fe stay in my system after I stop taking it?

A: The hormonal components are rapidly absorbed and undergo extensive metabolism primarily by the liver. The drug and its byproducts are primarily eliminated from the body through urine and feces within a known timeframe, but the specific duration varies based on individual factors.

How should Larin Fe be stored and disposed of?

How to Store and Dispose of Larin Fe?

Larin Fe must be stored according to specific regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

Storage Requirement Official Condition
Temperature Store at 20 C to 25 C (68 F to 77 F). Excursions permitted from 15 C to 30 C.
Protection Protect from light.

Store this medication in its original blister packaging at controlled room temperature and away from excessive heat or moisture. It is crucial to keep this and all medications out of the sight and reach of children and pets, particularly due to the presence of iron (ferrous fumarate) in the product.

Disposal Instructions

Do not flush Larin Fe down a toilet or pour it into a drain unless instructed to do so by a healthcare professional or government program. Properly dispose of unused or expired medicine by following guidance from your local drug take-back program. If a program is unavailable, consult patient labeling for instructions on how to dispose of the medication in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Larin Fe found in:

A-Z Index: